Replies to post #338 on Trillium Therapeutics Inc (TRIL)

[NY1972]

Looking at invivo data, I believe this is more likely:

The company felt compelled to remove the statement due to concern that this can taint (and perhaps disqualify) an abstract at a future scientific meeting

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=124985734